Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size Growth Rate by Type: 2018 VS 2022 VS 2033
1.2.2 Angiogenesis Inhibitor
1.2.3 Epidermal Growth Factor Receptor Blocker
1.2.4 Kinase Inhibitor
1.2.5 Microtubule Stabilizer
1.2.6 Folate Antimetabolites
1.2.7 Others
1.3 Market by Application
1.3.1 Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Growth by Application: 2018 VS 2022 VS 2033
1.3.2 Adenocarcinoma
1.3.3 Squamous Cell Carcinoma
1.3.4 Large Cell Carcinoma
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Perspective (2018-2033)
2.2 Non-Small Cell Lung Cancer Treatment (NSCLC) Growth Trends by Region
2.2.1 Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 Non-Small Cell Lung Cancer Treatment (NSCLC) Historic Market Size by Region (2018-2023)
2.2.3 Non-Small Cell Lung Cancer Treatment (NSCLC) Forecasted Market Size by Region (2024-2033)
2.3 Non-Small Cell Lung Cancer Treatment (NSCLC) Market Dynamics
2.3.1 Non-Small Cell Lung Cancer Treatment (NSCLC) Industry Trends
2.3.2 Non-Small Cell Lung Cancer Treatment (NSCLC) Market Drivers
2.3.3 Non-Small Cell Lung Cancer Treatment (NSCLC) Market Challenges
2.3.4 Non-Small Cell Lung Cancer Treatment (NSCLC) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Non-Small Cell Lung Cancer Treatment (NSCLC) Players by Revenue
3.1.1 Global Top Non-Small Cell Lung Cancer Treatment (NSCLC) Players by Revenue (2018-2023)
3.1.2 Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue Market Share by Players (2018-2023)
3.2 Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue
3.4 Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Concentration Ratio
3.4.1 Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue in 2022
3.5 Non-Small Cell Lung Cancer Treatment (NSCLC) Key Players Head office and Area Served
3.6 Key Players Non-Small Cell Lung Cancer Treatment (NSCLC) Product Solution and Service
3.7 Date of Enter into Non-Small Cell Lung Cancer Treatment (NSCLC) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Non-Small Cell Lung Cancer Treatment (NSCLC) Breakdown Data by Type
4.1 Global Non-Small Cell Lung Cancer Treatment (NSCLC) Historic Market Size by Type (2018-2023)
4.2 Global Non-Small Cell Lung Cancer Treatment (NSCLC) Forecasted Market Size by Type (2024-2033)
5 Non-Small Cell Lung Cancer Treatment (NSCLC) Breakdown Data by Application
5.1 Global Non-Small Cell Lung Cancer Treatment (NSCLC) Historic Market Size by Application (2018-2023)
5.2 Global Non-Small Cell Lung Cancer Treatment (NSCLC) Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size (2018-2033)
6.2 North America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Growth Rate by Country: 2018 VS 2022 VS 2033
6.3 North America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Country (2018-2023)
6.4 North America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Country (2024-2033)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size (2018-2033)
7.2 Europe Non-Small Cell Lung Cancer Treatment (NSCLC) Market Growth Rate by Country: 2018 VS 2022 VS 2033
7.3 Europe Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Country (2018-2023)
7.4 Europe Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Country (2024-2033)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size (2018-2033)
8.2 Asia-Pacific Non-Small Cell Lung Cancer Treatment (NSCLC) Market Growth Rate by Region: 2018 VS 2022 VS 2033
8.3 Asia-Pacific Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Region (2018-2023)
8.4 Asia-Pacific Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Region (2024-2033)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size (2018-2033)
9.2 Latin America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Growth Rate by Country: 2018 VS 2022 VS 2033
9.3 Latin America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Country (2018-2023)
9.4 Latin America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Country (2024-2033)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size (2018-2033)
10.2 Middle East & Africa Non-Small Cell Lung Cancer Treatment (NSCLC) Market Growth Rate by Country: 2018 VS 2022 VS 2033
10.3 Middle East & Africa Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Country (2018-2023)
10.4 Middle East & Africa Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Country (2024-2033)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AbbVie Inc.
11.1.1 AbbVie Inc. Company Detail
11.1.2 AbbVie Inc. Business Overview
11.1.3 AbbVie Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Introduction
11.1.4 AbbVie Inc. Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2018-2023)
11.1.5 AbbVie Inc. Recent Development
11.2 Astellas Pharma
11.2.1 Astellas Pharma Company Detail
11.2.2 Astellas Pharma Business Overview
11.2.3 Astellas Pharma Non-Small Cell Lung Cancer Treatment (NSCLC) Introduction
11.2.4 Astellas Pharma Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2018-2023)
11.2.5 Astellas Pharma Recent Development
11.3 AstraZeneca
11.3.1 AstraZeneca Company Detail
11.3.2 AstraZeneca Business Overview
11.3.3 AstraZeneca Non-Small Cell Lung Cancer Treatment (NSCLC) Introduction
11.3.4 AstraZeneca Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2018-2023)
11.3.5 AstraZeneca Recent Development
11.4 Avid Bioservices Inc.
11.4.1 Avid Bioservices Inc. Company Detail
11.4.2 Avid Bioservices Inc. Business Overview
11.4.3 Avid Bioservices Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Introduction
11.4.4 Avid Bioservices Inc. Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2018-2023)
11.4.5 Avid Bioservices Inc. Recent Development
11.5 Bayer Healthcare
11.5.1 Bayer Healthcare Company Detail
11.5.2 Bayer Healthcare Business Overview
11.5.3 Bayer Healthcare Non-Small Cell Lung Cancer Treatment (NSCLC) Introduction
11.5.4 Bayer Healthcare Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2018-2023)
11.5.5 Bayer Healthcare Recent Development
11.6 Biogen Inc.
11.6.1 Biogen Inc. Company Detail
11.6.2 Biogen Inc. Business Overview
11.6.3 Biogen Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Introduction
11.6.4 Biogen Inc. Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2018-2023)
11.6.5 Biogen Inc. Recent Development
11.7 Blueprint Medicines Corp
11.7.1 Blueprint Medicines Corp Company Detail
11.7.2 Blueprint Medicines Corp Business Overview
11.7.3 Blueprint Medicines Corp Non-Small Cell Lung Cancer Treatment (NSCLC) Introduction
11.7.4 Blueprint Medicines Corp Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2018-2023)
11.7.5 Blueprint Medicines Corp Recent Development
11.8 Eli Lilly and Company
11.8.1 Eli Lilly and Company Company Detail
11.8.2 Eli Lilly and Company Business Overview
11.8.3 Eli Lilly and Company Non-Small Cell Lung Cancer Treatment (NSCLC) Introduction
11.8.4 Eli Lilly and Company Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2018-2023)
11.8.5 Eli Lilly and Company Recent Development
11.9 Merck & co Inc.
11.9.1 Merck & co Inc. Company Detail
11.9.2 Merck & co Inc. Business Overview
11.9.3 Merck & co Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Introduction
11.9.4 Merck & co Inc. Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2018-2023)
11.9.5 Merck & co Inc. Recent Development
11.10 Novartis
11.10.1 Novartis Company Detail
11.10.2 Novartis Business Overview
11.10.3 Novartis Non-Small Cell Lung Cancer Treatment (NSCLC) Introduction
11.10.4 Novartis Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2018-2023)
11.10.5 Novartis Recent Development
11.11 Pfizer Inc.
11.11.1 Pfizer Inc. Company Detail
11.11.2 Pfizer Inc. Business Overview
11.11.3 Pfizer Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Introduction
11.11.4 Pfizer Inc. Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2018-2023)
11.11.5 Pfizer Inc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2033
Table 2. Key Players of Angiogenesis Inhibitor
Table 3. Key Players of Epidermal Growth Factor Receptor Blocker
Table 4. Key Players of Kinase Inhibitor
Table 5. Key Players of Microtubule Stabilizer
Table 6. Key Players of Folate Antimetabolites
Table 7. Key Players of Others
Table 8. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2033
Table 9. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Region (US$ Million): 2018 VS 2022 VS 2033
Table 10. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Region (2018-2023) & (US$ Million)
Table 11. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Region (2018-2023)
Table 12. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 13. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Region (2024-2033)
Table 14. Non-Small Cell Lung Cancer Treatment (NSCLC) Market Trends
Table 15. Non-Small Cell Lung Cancer Treatment (NSCLC) Market Drivers
Table 16. Non-Small Cell Lung Cancer Treatment (NSCLC) Market Challenges
Table 17. Non-Small Cell Lung Cancer Treatment (NSCLC) Market Restraints
Table 18. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue by Players (2018-2023) & (US$ Million)
Table 19. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Players (2018-2023)
Table 20. Global Top Non-Small Cell Lung Cancer Treatment (NSCLC) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) as of 2022)
Table 21. Ranking of Global Top Non-Small Cell Lung Cancer Treatment (NSCLC) Companies by Revenue (US$ Million) in 2022
Table 22. Global 5 Largest Players Market Share by Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue (CR5 and HHI) & (2018-2023)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Non-Small Cell Lung Cancer Treatment (NSCLC) Product Solution and Service
Table 25. Date of Enter into Non-Small Cell Lung Cancer Treatment (NSCLC) Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Type (2018-2023) & (US$ Million)
Table 28. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue Market Share by Type (2018-2023)
Table 29. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 30. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue Market Share by Type (2024-2033)
Table 31. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Application (2018-2023) & (US$ Million)
Table 32. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue Market Share by Application (2018-2023)
Table 33. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 34. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue Market Share by Application (2024-2033)
Table 35. North America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 36. North America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Country (2018-2023) & (US$ Million)
Table 37. North America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Country (2024-2033) & (US$ Million)
Table 38. Europe Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 39. Europe Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Country (2018-2023) & (US$ Million)
Table 40. Europe Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Country (2024-2033) & (US$ Million)
Table 41. Asia-Pacific Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2033
Table 42. Asia-Pacific Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Region (2018-2023) & (US$ Million)
Table 43. Asia-Pacific Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Region (2024-2033) & (US$ Million)
Table 44. Latin America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 45. Latin America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Country (2018-2023) & (US$ Million)
Table 46. Latin America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Country (2024-2033) & (US$ Million)
Table 47. Middle East & Africa Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 48. Middle East & Africa Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Country (2018-2023) & (US$ Million)
Table 49. Middle East & Africa Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Country (2024-2033) & (US$ Million)
Table 50. AbbVie Inc. Company Detail
Table 51. AbbVie Inc. Business Overview
Table 52. AbbVie Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Product
Table 53. AbbVie Inc. Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2018-2023) & (US$ Million)
Table 54. AbbVie Inc. Recent Development
Table 55. Astellas Pharma Company Detail
Table 56. Astellas Pharma Business Overview
Table 57. Astellas Pharma Non-Small Cell Lung Cancer Treatment (NSCLC) Product
Table 58. Astellas Pharma Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2018-2023) & (US$ Million)
Table 59. Astellas Pharma Recent Development
Table 60. AstraZeneca Company Detail
Table 61. AstraZeneca Business Overview
Table 62. AstraZeneca Non-Small Cell Lung Cancer Treatment (NSCLC) Product
Table 63. AstraZeneca Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2018-2023) & (US$ Million)
Table 64. AstraZeneca Recent Development
Table 65. Avid Bioservices Inc. Company Detail
Table 66. Avid Bioservices Inc. Business Overview
Table 67. Avid Bioservices Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Product
Table 68. Avid Bioservices Inc. Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2018-2023) & (US$ Million)
Table 69. Avid Bioservices Inc. Recent Development
Table 70. Bayer Healthcare Company Detail
Table 71. Bayer Healthcare Business Overview
Table 72. Bayer Healthcare Non-Small Cell Lung Cancer Treatment (NSCLC) Product
Table 73. Bayer Healthcare Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2018-2023) & (US$ Million)
Table 74. Bayer Healthcare Recent Development
Table 75. Biogen Inc. Company Detail
Table 76. Biogen Inc. Business Overview
Table 77. Biogen Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Product
Table 78. Biogen Inc. Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2018-2023) & (US$ Million)
Table 79. Biogen Inc. Recent Development
Table 80. Blueprint Medicines Corp Company Detail
Table 81. Blueprint Medicines Corp Business Overview
Table 82. Blueprint Medicines Corp Non-Small Cell Lung Cancer Treatment (NSCLC) Product
Table 83. Blueprint Medicines Corp Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2018-2023) & (US$ Million)
Table 84. Blueprint Medicines Corp Recent Development
Table 85. Eli Lilly and Company Company Detail
Table 86. Eli Lilly and Company Business Overview
Table 87. Eli Lilly and Company Non-Small Cell Lung Cancer Treatment (NSCLC) Product
Table 88. Eli Lilly and Company Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2018-2023) & (US$ Million)
Table 89. Eli Lilly and Company Recent Development
Table 90. Merck & co Inc. Company Detail
Table 91. Merck & co Inc. Business Overview
Table 92. Merck & co Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Product
Table 93. Merck & co Inc. Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2018-2023) & (US$ Million)
Table 94. Merck & co Inc. Recent Development
Table 95. Novartis Company Detail
Table 96. Novartis Business Overview
Table 97. Novartis Non-Small Cell Lung Cancer Treatment (NSCLC) Product
Table 98. Novartis Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2018-2023) & (US$ Million)
Table 99. Novartis Recent Development
Table 100. Pfizer Inc. Company Detail
Table 101. Pfizer Inc. Business Overview
Table 102. Pfizer Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Product
Table 103. Pfizer Inc. Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2018-2023) & (US$ Million)
Table 104. Pfizer Inc. Recent Development
Table 105. Research Programs/Design for This Report
Table 106. Key Data Information from Secondary Sources
Table 107. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size Comparison by Type (2023-2033) & (US$ Million)
Figure 2. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Type: 2022 VS 2033
Figure 3. Angiogenesis Inhibitor Features
Figure 4. Epidermal Growth Factor Receptor Blocker Features
Figure 5. Kinase Inhibitor Features
Figure 6. Microtubule Stabilizer Features
Figure 7. Folate Antimetabolites Features
Figure 8. Others Features
Figure 9. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size Comparison by Application (2023-2033) & (US$ Million)
Figure 10. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Application: 2022 VS 2033
Figure 11. Adenocarcinoma Case Studies
Figure 12. Squamous Cell Carcinoma Case Studies
Figure 13. Large Cell Carcinoma Case Studies
Figure 14. Non-Small Cell Lung Cancer Treatment (NSCLC) Report Years Considered
Figure 15. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 16. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 17. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Region: 2022 VS 2033
Figure 18. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Players in 2022
Figure 19. Global Top Non-Small Cell Lung Cancer Treatment (NSCLC) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) as of 2022)
Figure 20. The Top 10 and 5 Players Market Share by Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue in 2022
Figure 21. North America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 22. North America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Country (2018-2033)
Figure 23. United States Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 24. Canada Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 25. Europe Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 26. Europe Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Country (2018-2033)
Figure 27. Germany Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 28. France Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 29. U.K. Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 30. Italy Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 31. Russia Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 32. Nordic Countries Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 33. Asia-Pacific Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 34. Asia-Pacific Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Region (2018-2033)
Figure 35. China Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 36. Japan Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 37. South Korea Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 38. Southeast Asia Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 39. India Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 40. Australia Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 41. Latin America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 42. Latin America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Country (2018-2033)
Figure 43. Mexico Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 44. Brazil Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 45. Middle East & Africa Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 46. Middle East & Africa Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Country (2018-2033)
Figure 47. Turkey Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 48. Saudi Arabia Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 49. AbbVie Inc. Revenue Growth Rate in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2018-2023)
Figure 50. Astellas Pharma Revenue Growth Rate in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2018-2023)
Figure 51. AstraZeneca Revenue Growth Rate in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2018-2023)
Figure 52. Avid Bioservices Inc. Revenue Growth Rate in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2018-2023)
Figure 53. Bayer Healthcare Revenue Growth Rate in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2018-2023)
Figure 54. Biogen Inc. Revenue Growth Rate in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2018-2023)
Figure 55. Blueprint Medicines Corp Revenue Growth Rate in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2018-2023)
Figure 56. Eli Lilly and Company Revenue Growth Rate in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2018-2023)
Figure 57. Merck & co Inc. Revenue Growth Rate in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2018-2023)
Figure 58. Novartis Revenue Growth Rate in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2018-2023)
Figure 59. Pfizer Inc. Revenue Growth Rate in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2018-2023)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed